NL-OMON21406已完成不适用
Hydroxychloroquine as an anti-autophagy and chromatin modulating drug in combination with erlotinib in non-small cell lung cancer (NSCLC) patients: a single-center single arm open-label phase II trial.
VU University Medical Center0 个研究点目标入组 136 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 136
研究概览
简要总结
/A
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Histologically confirmed stage IV non-squamous NSCLC patients;
- •2. Patients:
排除标准
- •See inclusion criteria.
研究者
相似试验
进行中（未招募）
不适用
Treatment with hydroxychloroquine and erlotinib in patients with non-small-cell lung cancerPatients with histologically confirmed stage IV non-squamous non-small-cell lung cancer (NSCLC)• with an activating EGFR mutation who progressed on erlotinib or gefitinib monotherapy. OR• who failed after at least one line of platinum based doublet chemotherapy and who are EGFR TKI naïve.EUCTR2011-004903-20-NL136
已完成
2 期
Hydroxychloroquine as an anti-autophagy and chromatin modulating drug in combination with erlotinib in non-small cell lung cancer (NSCLC) patients: a single-center single arm open-label phase II trialAdvanced stage NSCLCMetastatic NSCLC10038666NL-OMON37508Vrije Universiteit Medisch Centrum136
进行中（未招募）
1 期
Autophagy inhibition using hydrochloroquine in breast cancer patients: a pilot study - HCQ TRIAEUCTR2010-022842-26-NLniversity Medical Centre Nijmegen20
招募中
2 期
Autophagy inhibition using hydrochloroquine in breast cancer patients: a pilot study10006291breast cancerNL-OMON34049niversitair Medisch Centrum Sint Radboud20
已完成
不适用
Chloroquine as an anti-autophagic chemosensitizing drug in stage IV small cell lung cancer (SCLC) patients: A phase I trial.10029107small cell lung cancerNL-OMON37990MAASTRO clinic24